303 related articles for article (PubMed ID: 11825540)
41. Primary sclerosing cholangitis.
Stiehl A; Benz C; Sauer P
Can J Gastroenterol; 2000 Apr; 14(4):311-5. PubMed ID: 10799084
[TBL] [Abstract][Full Text] [Related]
42. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
43. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
[TBL] [Abstract][Full Text] [Related]
44. [Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis].
Avezov SA; Mansurova FKh
Klin Med (Mosk); 2004; 82(2):46-9. PubMed ID: 15106512
[TBL] [Abstract][Full Text] [Related]
45. Ursodeoxycholic acid in chronic liver disease.
de Caestecker JS; Jazrawi RP; Petroni ML; Northfield TC
Gut; 1991 Sep; 32(9):1061-5. PubMed ID: 1916492
[TBL] [Abstract][Full Text] [Related]
46. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
[TBL] [Abstract][Full Text] [Related]
47. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study.
Fabris P; Tositti G; Mazzella G; Zanetti AR; Nicolin R; Pellizzer G; Benedetti P; de Lalla F
Aliment Pharmacol Ther; 1999 Sep; 13(9):1187-93. PubMed ID: 10468700
[TBL] [Abstract][Full Text] [Related]
48. Intrahepatic cholestasis of pregnancy: changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid.
Brites D
Ann Hepatol; 2002; 1(1):20-8. PubMed ID: 15114292
[TBL] [Abstract][Full Text] [Related]
49. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.
Sinakos E; Marschall HU; Kowdley KV; Befeler A; Keach J; Lindor K
Hepatology; 2010 Jul; 52(1):197-203. PubMed ID: 20564380
[TBL] [Abstract][Full Text] [Related]
50. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
[TBL] [Abstract][Full Text] [Related]
51. [Cholestatic liver diseases].
Reichel C; Meier-Abt PJ
Ther Umsch; 1997 Nov; 54(11):639-44. PubMed ID: 9454366
[TBL] [Abstract][Full Text] [Related]
52. Effects of chenodeoxycholic and ursodeoxycholic acids on interferon-gamma production by peripheral blood mononuclear cells from patients with primary biliary cirrhosis.
Saeki R; Ogino H; Kaneko S; Unoura M; Kobayashi K
J Gastroenterol; 1995 Dec; 30(6):739-44. PubMed ID: 8963391
[TBL] [Abstract][Full Text] [Related]
53. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis.
Scher H; Bishop WP; McCray PB
Ann Pharmacother; 1997 Sep; 31(9):1003-5. PubMed ID: 9296240
[TBL] [Abstract][Full Text] [Related]
54. Increase of sulfated ursodeoxycholic acid in the serum and urine of patients with chronic liver disease after ursodeoxycholic acid therapy.
Nakamura K; Yoneda M; Kimura A; Tamori K; Yokohama S; Sato Y; Kato T; Hasegawa T; Saito H; Aoshima M; Fujita M; Makino I
J Gastroenterol Hepatol; 1996 Apr; 11(4):385-90. PubMed ID: 8713707
[TBL] [Abstract][Full Text] [Related]
55. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
[TBL] [Abstract][Full Text] [Related]
56. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
57. [Treatment of cholestatic liver diseases; the role of ursodeoxycholic acid].
Stiehl A
Z Gastroenterol; 1992 Oct; 30(10):743-7. PubMed ID: 1441678
[TBL] [Abstract][Full Text] [Related]
58. Cystic fibrosis. Is treatment with ursodeoxycholic acid of value?
Strandvik B; Lindblad A
Scand J Gastroenterol Suppl; 1994; 204():65-7. PubMed ID: 7824881
[TBL] [Abstract][Full Text] [Related]
59. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
[TBL] [Abstract][Full Text] [Related]
60. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]